Novantrone Proposed Dosing For MS Could Lead To Two-Year Treatment Limit

Immunex should study Novantrone at lower doses and a higher cumulative dose to overcome the limitation of a potential two-year cap on use of the mitoxantrone drug for treatment in multiple sclerosis, members of FDA's Peripheral & Central Nervous System Drugs Advisory Committee and the agency suggested Jan. 28.